J&J hopes to supply more than one billion doses worldwide over the course of next year. Credit: pearson0612 from Pixabay.

Johnson & Johnson (J&J) unit Janssen Pharmaceutical has signed an agreement with the US Government for the large scale domestic production and supply of 100 million doses of its Covid-19 vaccine candidate, Ad26.COV2.S.

The vaccine, based on Janssen AdVac technology, will be used in the US after it secures regulatory approval or emergency use authorisation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

For this agreement, the US Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense have committed to providing more than $1bn.

The government may buy an additional 200 million doses of the vaccine in the future.

Johnson & Johnson chief scientific officer Paul Stoffels said: “Johnson & Johnson’s global team of experts has worked tirelessly alongside BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to stop the spread of Covid-19.

“We greatly appreciate the US government’s confidence in, and support for, our R&D platform and efforts and the scalability of our vaccine technology. We are scaling up production in the US and worldwide to deliver a SARS-CoV-2 vaccine for emergency use.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is developing the vaccine candidate as part of an ongoing research and development collaboration with BARDA. The product is currently in Phase I / IIa clinical trial in the US and Belgium.

If the vaccine is safe and effective, J&J hopes to supply more than one billion doses worldwide over the course of next year.

Last month, J&J said that the company is in discussions with the Government of Japan, as well as the Bill and Melinda Gates Foundation, regarding allocations of its Covid-19 vaccine candidate.

The US government already signed similar Covid-19 vaccine supply deals with Sanofi and GlaxoSmithKline (GSK), as well as Pfizer and BioNTech.